---
layout: page
permalink: /literature/index.html
title: Literature
---

## Microglia | Microgliosis

<br>

2025 ***Nat Neurosci***. *Marco Prinz*. Response of spatially defined microglia states with distinct chromatin accessibility in a mouse model of Alzheimer’s disease

小胶质细胞的空间异质性仍然是一个关键问题，尤其在**阿尔茨海默病**（AD）潜在的细胞导向疗法中，这一问题尚未得到完全解答。对于靠近或远离β-淀粉样蛋白（Aβ）斑块的不同小胶质细胞状态及其对神经退行性疾病的贡献，尚未有清晰的理解。在本研究中，我们结合了**多色荧光细胞命运追踪**、**单细胞转录分析**、**表观遗传学分析**、**免疫组化和计算建模**，全面描述了斑块相关小胶质细胞（**PAM**）和非斑块相关小胶质细胞（non-PAM）在阿尔茨海默小鼠模型中的关系。我们发现，non-PAM是一个独特且高度动态的小胶质细胞状态，在雌性小鼠Aβ斑块沉积后转变为PAM。Non-PAM在应对淀粉样沉积时调节细胞群体的扩展，并迅速响应环境信号。事实上，**Csf1**信号通路在疾病进程中调节non-PAM向PAM的转变。我们的数据表明，小胶质细胞状态及其相互之间的动态变化可能对疾病产生不同的贡献，且这些状态可能成为阿尔茨海默病治疗的潜在靶点。

<br>2025 ***Cell Rep***. *Vanessa Coelho-Santos*. Physiological and injury-induced  microglial dynamics across the lifespan

<img src="E:\Personal_website\mushan-guan.github.io\academic\img3.png" style="zoom: 67%;" />

通过**双光子活体成像**，确认在成年大脑皮层，小胶质细胞在基础状态下展现出高度分支的突起和相对静止的细胞体。它们对**激光诱导的局部损伤**的反应发生在几分钟内，并且邻近的小胶质细胞之间协调性很高。相比之下，新生小胶质细胞较为密集且更具活动性，但形态复杂性较低。它们对毛细血管或实质组织的激光诱导局部损伤反应缺乏协调性，反应延迟且持续数天。在衰老的大脑中，小胶质细胞的细胞体在基础状态下保持不动，但它们的突起变得较少分支。它们对局部损伤的反应是协调的，但较慢且不太敏感。这些研究揭示了小胶质细胞在整个生命周期中的形态、分布、动态变化和损伤反应的显著变化。

**(成年期小胶分支较多且对脑实质或血管损伤反应较快，而新生期小胶和衰老期小胶的形态比较接近，都是分支较少，且对损伤反应都较慢。但新生期小胶动力学更加活跃，胞体密度更大且移动性更高，分支的伸缩长度与伸缩速度更高，而衰老期小胶动力学更加静默。)**

小胶质细胞是大脑的常驻免疫细胞，具有在秒到分钟的快速时间尺度上改变其形态的独特能力。它们在神经发育、免疫监视以及对组织损伤的反应中发挥着多样化的作用。小胶质细胞来源于单核细胞/巨噬细胞谱系，其前体细胞来源于脑膜巨噬细胞和间充质组织，在胚胎和早期出生后的时期进入中枢神经系统，且在血脑屏障（BBB）闭合之前完成这一过程。

在发育过程中，小胶质细胞通过修剪多余的神经突触以及促进细胞分化和成熟，塑造神经回路。在成年期，小胶质细胞继续通过随着感官经验的变化修改突触，塑造神经连接性。

在小鼠大脑发育的第一后天周，小胶质细胞表现为阿米巴样形态，突起的分支有限。它们在塑造大脑结构过程中发挥着清除细胞残骸的吞噬作用。此外，对发育中大脑中小胶质细胞与血管的物理关联的观察表明，它们可能支持微血管结构和功能的发育，并可能利用血管迁移进入大脑。在接下来的几周里，小胶质细胞经历了从阿米巴样形态向成熟的静息小胶质细胞的形态转变，成熟的小胶质细胞的特点是细小的细胞体和从细胞体放射状延伸的细长且高度分支的突起。

在成年大脑中，小胶质细胞帮助维持大脑稳态和调节神经环境。作为大脑固有免疫系统的一部分，小胶质细胞能够识别损伤或病原，并迅速启动炎症反应。它们迅速延伸突起并迁移到损伤部位，充当损伤组织与健康组织之间的屏障。**小胶质细胞还会在响应损伤时重新获得类似发育时期的阿米巴样形态**。小胶质细胞的免疫反应如果协调良好，可以在伤口愈合过程中发挥有益作用，通过清除细胞残骸、提供神经保护以及限制损伤血管中血液分子的外渗。然而，小胶质细胞的激活可能是有益的，也可能是有害的，这取决于应激和损伤信号的类型、损伤的持续时间、组织微环境以及机体的年龄。

随着大脑的衰老，小胶质细胞的分支变得较少。衰老的小胶质细胞还增加了与神经保护相关的基因表达，表明它们对伴随衰老的退行性过程做出了补偿性反应。然而，小胶质细胞也可能变得衰老或萎缩，表现为神经保护功能降低、促炎细胞因子释放增加以及抗炎信号通路减少，这些变化有助于慢性炎症状态、神经元功能障碍和细胞死亡的发生。

<br>

2024 ***Sci Adv***. *高艳琴*. Arresting the bad seed: HDAC3 regulates proliferation  of different microglia after ischemic stroke

在缺血性脑卒中后，梗死半暗带中自我更新的极化小胶质细胞的积聚是一种关键的神经炎症过程，会导致继发性脱髓鞘和神经元丧失。尽管已知HDAC3在调控肿瘤细胞增殖和神经炎症中发挥作用，其在小胶质细胞增生和极化中的角色仍不清楚。我们的研究表明，敲除小胶质细胞中的HDAC3（HDAC3-miKO）可改善卒中后的长期功能和组织学结局。RNA测序分析显示，在卒中后，HDAC3缺失小胶质细胞中受影响的主要过程是有丝分裂。值得注意的是，HDAC3-miKO特异性地抑制了促炎型小胶质细胞的增殖，而不影响抗炎型小胶质细胞，从而阻止了小胶质细胞向促炎状态的转变。此外，ATAC-seq分析显示，HDAC3-miKO引起了富含PU.1转录因子结合位点的可及染色质区域的关闭。通过AAV手段过表达小胶质细胞中的PU.1逆转了HDAC3-miKO引起的增殖抑制和卒中保护效应，表明PU.1是介导HDAC3调控卒中作用的下游分子。这些发现揭示了HDAC3/PU.1轴介导了不同小胶质细胞群体间与增殖相关的程序重编程，驱动了卒中后的炎症状态转变，并参与了缺血性脑卒中的发病机制。

PU.1在中枢神经系统中其表达仅限于小胶质细胞，控制小胶质细胞的发育与功能。早期的小胶质细胞发生依赖于PU.1的表达水平。此外，研究还证实PU.1是调控造血干细胞中多个细胞周期基因的关键转录因子，而这些干细胞是巨噬细胞的发源细胞。值得注意的是，在啮齿类小胶质细胞系BV2中，对PU.1的敲低或过表达可以识别出一系列与神经炎症相关的差异表达基因。在多种神经系统疾病中，抑制PU.1的活性有可能限制小胶质细胞介导的神经炎症反应。

在本研究中，我们发现，除了如先前报道所示恢复小胶质细胞极化外，HDAC3的缺失还能通过诱导G2-M期的细胞周期阻滞，从而抑制卒中后小胶质细胞的急性增殖。值得注意的是，HDAC3敲除使CD16⁺小胶质细胞的增殖被阻止，而Arg1⁺小胶质细胞则未表现出类似变化，提示HDAC3在不同小胶质细胞亚群增殖中的作用具有选择性。进一步地，我们结合RNA-seq与ATAC-seq，深入探讨了潜在的表观遗传机制，结果显示PU.1可能是参与HDAC3调控小胶质细胞增殖与极化的关键转录因子。因此，我们采用了一种新近开发的腺相关病毒（AAV）技术，该技术能特异性地靶向小胶质细胞，并发现通过该技术过表达小胶质细胞PU.1可逆转HDAC3敲除（HDAC3-miKO）所致的小胶质细胞增殖抑制效应及其对缺血性脑卒中的保护作用，进一步证实PU.1是HDAC3功能发挥的关键下游因子。总体而言，我们的研究揭示了小胶质细胞HDAC3的多重调控效应，并强调了“阻断小胶质细胞周期”这一此前在卒中研究中被严重低估的关键机制。这一发现不仅加深了我们对小胶质细胞多面性特征的理解，也扩展了我们对缺血性脑卒中炎症激活机制的认知，从而为相关治疗策略，甚至某些已有的抗增殖类药物的再利用打开了新窗口。

我们通过将HDAC3^flox/flox小鼠与CX3CR1^creER/wt小鼠交配，构建了HDAC3^flox/floxCX3CR1^creER/wt（即HDAC3-miKO）小鼠模型。在HDAC3-miKO小鼠中，只有在给予他莫昔芬之后，HDAC3才会被敲除，从而避免了HDAC3敲除对发育中脑组织的潜在影响。具体而言，他莫昔芬诱导在表达CX3CR1的细胞中敲除HDAC3，这些细胞包括小胶质细胞以及外周髓系细胞。然而，外周髓系细胞会持续被骨髓中CX3CR1⁻祖细胞替代，因此原始的HDAC3敲除巨噬细胞群在30天内几乎被完全更新；而小胶质细胞则依靠自我更新维持，并在整个生命周期中持续表达CX3CR1。因此，在所有后续实验中，我们均在他莫昔芬处理后第30天实施暂时性大脑中动脉闭塞模型（tFCI），以实现仅在小胶质细胞中敲除HDAC3，而不影响外周髓系细胞，从而明确验证小胶质细胞中HDAC3的特定功能。为了验证小胶质细胞中HDAC3敲除的效率，在他莫昔芬处理后第30天，我们采用荧光激活细胞分选（FACS）技术分离了脑组织中的小胶质细胞、其他脑细胞，以及外周血中的巨噬细胞。

值得注意的是，我们在tFCI后的第1天和第3天进行的行为学评估，以及第3天的MRI结果，似乎都表明小胶质细胞中HDAC3的缺失可能在早期阶段减轻了脑损伤，从而减少了小胶质细胞的丧失，并进一步降低了其增殖反应。为了排除这一可能性，我们将HDAC3-miKO小鼠的闭塞时间延长至90分钟，从而诱导出更大的梗死体积。为了检测tFCI后新生的小胶质细胞，我们采用了先前研究中所描述的腹腔注射EdU的方法。在接受90分钟闭塞处理的小鼠中，HDAC3缺失的小胶质细胞在tFCI后第3天仍表现出明显的自我更新障碍，这与接受60分钟闭塞处理的野生型小鼠中的小胶质细胞相比差异显著。这些结果表明，小胶质细胞的增殖潜力依赖于其所表达的HDAC3，而不是取决于初始脑损伤的严重程度。此外，为了进一步确定小胶质细胞数量减少是否也可能归因于其凋亡水平升高，我们使用TUNEL检测小胶质细胞的凋亡情况。结果显示，在纹状体梗死周边区域，HDAC3-miKO小鼠中TUNEL阳性（TUNEL⁺）凋亡小胶质细胞的数量显著减少，这意味着HDAC3缺失引起的小胶质细胞数量减少完全是由于其增殖缺陷所致，而非凋亡增加所引起。与之相一致的是，已有多项研究也报道了抑制HDAC3可以防止细胞凋亡的现象。





<br>

2023 ***Genome Med***. *徐运*. Acute ischemia induces spatially and transcriptionally distinct microglial subclusters





<br>

## Monocyte | Macrophage

<br>

2025 ***NC***. [*史利根*](https://person.zju.edu.cn/ligens). Repair-associated macrophages increase after early-phase microglia attenuation to promote ischemic stroke recovery

缺血性脑卒中的恢复过程涉及中枢神经系统与浸润性免疫细胞之间的动态相互作用。外周免疫细胞与脑内常驻的小胶质细胞在空间位点上存在竞争，但目前尚不清楚如何调节这种平衡会对卒中恢复产生何种影响。在本研究中，我们使用 PLX5622 在雄性小鼠短暂性大脑中动脉闭塞（tMCAO）模型中创造外周免疫细胞的空间位点，从而改变浸润免疫细胞与常驻小胶质细胞之间的竞争格局。我们发现，在卒中早期阶段抑制小胶质细胞可以促进长期功能恢复。该干预措施增强了**一类具有修复特性的单核细胞来源的巨噬细胞亚群**（repair-related macrophages, **RAMf**），该亚群表现出高表达 GPNMB 和 CD63、增强的脂质代谢以及促血管生成活性。将 RAMf 移植至中风小鼠体内可改善白质完整性并促进血管修复。我们进一步鉴定出 Mafb 是调控 RAMf 修复性表型的关键转录因子。这些发现强调了优化免疫细胞动态，以促进中风后康复的潜在治疗策略。

C57BL/6J MCAO小鼠PLX5622连续小胶清除7天，然后常规喂养到造模后第35天做行为学与梗死体积检测；

C57BL/6J MCAO小鼠PLX5622连续小胶清除5天，第5天确认清除效率，进行脑、外周血细胞单细胞测序、流式检查免疫细胞比例、检测梗死体积、脑白质完整性、血管新生情况，单细胞测序重点关注巨噬细胞、单核细胞；

C57BL/6J MCAO小鼠PLX5622连续小胶清除7天，然后常规喂养到造模后第14天脑细胞单细胞测序、检测梗死体积、脑白质完整性、血管新生情况，单细胞测序重点关注少突胶质细胞及其前体细胞、血管内皮细胞、小胶质细胞；

C57BL/6J MCAO小鼠PLX5622连续小胶清除7天，然后常规喂养到造模后第14天脑CD45high、外周血单细胞测序，重点关注巨噬细胞、单核细胞，发现RAMf并流式验证，轨迹Monocle3 & FateID、打分AUCell、细胞通讯InterCellDB、转录因子分析ARCHS4 & SCENIC；

Mafb-siRNA 骨髓来源巨噬细胞体外吞噬髓鞘能力减弱；

慢病毒过表达骨髓来源巨噬细胞Mafb然后bulk RNA测序，发现和RAMf基因表达类似，同时小鼠移植验证；

CCR2-GFP MCAO小鼠PLX5622连续小胶清除5天，第5天流式、染色验证RAMf的身份，使用clodronate liposomes清除单核细胞或CCR2-KO小鼠确认RAMf的外周单核起源，同时第5天做脂质组学确认RAMf对脂代谢的影响；

C57BL/6J MCAO小鼠在第5天接受RAMf移植在第14天取样发现促进髓鞘再生、白质完整性、血管重建；

老年MCAO小鼠第14天脑单细胞测序，挑出老年小鼠的巨噬细胞与年轻小鼠的巨噬细胞进行比较分析，发现老年小鼠也存在RAMf，并且可以通过早期小胶清除增加RAMf比例



<br>

## Astrocyte



<br>

## Oligodendrocyte | OPC | Demyelination | Remyelination



<br>

## Neuron | NPC | NSC



<br>

## Neutrophil

<br>

2023 ***Nat Immunol***. *Marco Bacigaluppi*. Age-induced alterations of granulopoiesis  generate atypical neutrophils that aggravate  stroke pathology



<br>

## T Lymphocyte

<br>

2025 **CMI**. *姚红红*. CD8+GZMK+CD27+CCR7+ T cells mobilized by splenic sympathetic nerves aggravate brain ischemia‒reperfusion injury via CCL19-positive endothelial cells

**脾脏交感神经**活动在缺血性卒中后对外周免疫有重要调节作用，因此，干预脾脏交感神经活动是一种有前景的中风治疗策略。然而，脾脏-大脑-免疫轴的通信机制仍不完全明确。在本研究中，我们采用外科去神经化方案进行**脾脏交感神经去神经化（SDN）**，结果显著减轻了中风后的脑损伤。通过**单细胞RNA测序**，我们在急性缺血性卒中（AIS）患者中鉴定出了一种新型的GZMK+CD8+CD27+CCR7+ T细胞亚群，我们命名为**中风相关T细胞（Tsa）**。Tsa细胞的扩增与临床症状的严重程度呈正相关，且由脾脏交感神经系统驱动。中风引起的交感神经激活触发了脾脏去甲肾上腺素（NE）的释放，NE优先通过ADRB2与Tsa细胞结合，促进其动员。此外，缺血性损伤诱导了**内皮细胞特异性表达CCL19**，CCL19通过与Tsa细胞的CCR7受体结合，化学引导Tsa细胞进入脑实质，加剧了神经炎症损伤和神经功能缺损，在暂时性大脑中动脉闭塞（tMCAO）小鼠模型中得到了验证。我们开发了一种CCR7靶向肽，通过干扰这一趋化轴，减少了T细胞浸润，从而减轻了脑损伤。我们的研究结果突出了脾脏交感神经去神经化作为一种有前景的治疗策略，能够减轻缺血-再灌注损伤，并表明其作为急性缺血性卒中患者再灌注治疗的辅助治疗的潜力。

脾脏是系统性免疫反应的核心器官，作为各种免疫细胞的储库，据信在中风后是中枢神经系统与外周免疫系统之间的第一个联系点。临床研究报告显示，大约40%的急性缺血性中风（AIS）患者脾脏体积显著减少，其中脾脏收缩的患者血液中淋巴细胞比例增加，并且炎症细胞因子水平升高。大量证据表明，脾脏来源的炎症细胞被释放并渗透到缺血的大脑中，作为促炎因子加剧脑损伤。调节脾脏活动已成为一个有前景的治疗靶点，具有减轻脑部炎症损伤并改善AIS后预后的潜力。脾脏切除术、脾脏脉冲超声治疗和脾脏辐射治疗在动物中风模型中已广泛用于抑制脾脏功能，并已证明具有神经保护作用。然而，由于这些方法会永久性地消除脾脏功能，从而对免疫状态和患者的整体健康产生不可逆的后果，因此在临床实践中受到限制。血管内去神经化，包括血管内脾脏交感神经去神经化（SDN），在动物模型中已显示出有希望的结果，因其有效性、安全性和可行性。因此，目前它正在考虑用于针对炎症疾病的临床试验。进一步的研究确认脾脏交感神经信号在中风后调节先天性和适应性免疫反应中发挥着关键作用。然而，SDN对中风引起的脑损伤的神经保护能力及其机制尚未完全阐明。AIS中的免疫反应功能受到了越来越多的关注，T淋巴细胞成为了有害和修复性免疫反应的关键介导者。积累的证据支持T淋巴细胞在脑缺血反应中的多面角色。尽管早期研究已经确定外周T细胞浸润到缺血大脑是中风后免疫激活的标志，但最近的进展进一步阐明了不同T细胞亚群的细致贡献。CD4+辅助性T细胞分泌IFN-γ和IL-21，这些细胞因子的缺乏显著减轻了实验性中风模型中的脑梗塞体积。CD8+细胞毒性T淋巴细胞（CTLs）通过颗粒酶B和穿孔素的释放放大神经毒性，而调节性T细胞（Tregs）通过骨桥蛋白–整合素信号通路激活小胶质细胞修复通路，促进白质修复。这些更新突出了T细胞亚群在AIS病理生理中的复杂相互作用；然而，SDN是否影响免疫细胞的变化仍然未知。

在本研究中，我们采用外科去神经化方案，在中风小鼠模型中进行脾脏交感神经去神经化（SDN），并报告了SDN在中风背景下有效减少缺血‒再灌注损伤。接下来，我们对AIS患者在再灌注治疗前后外周血单核细胞（PBMCs）的单细胞RNA测序（scRNA-seq）数据进行了无偏分析。我们鉴定出AIS患者中一个之前未被识别的GZMK+CD8+CD27+CCR7+ T细胞亚群，命名为中风相关T细胞（Tsa），该亚群的扩增与临床症状的严重程度显著正相关。中风引起的交感神经激活触发脾脏去甲肾上腺素（NE）的释放，NE通过β2-肾上腺素受体（ADRB2）选择性地信号化，驱动Tsa细胞的动员。随后，Tsa细胞通过中风后特定内皮细胞亚群分泌的CCL19通过CCL19/CCR7轴进行脑内渗透。因此，脑内Tsa细胞放大了神经炎症，且这种致病级联反应通过CCR7靶向肽抑制剂有效地被中断。我们的研究表明，SDN作为一种临床可行的策略，能够优化再灌注结果，同时识别CCR7抑制作为平行的治疗途径。





<br>

## B Lymphocyte





<br>

## Endothelium | Angiogenesis



<br>

## Erythrocyte | HSC



<br>

## CNS tumor



<br>

## 淋巴特异性解旋酶 HELLS | LSH

<br>

2025 Trends Cell Biol. Valentina Fragliasso. HELLS: the transcriptional sentinel

染色质重塑因子HELLS的作用历来与 DNA甲基化和DNA损伤修复相关。最近的研究揭示了HELLS在转录调控中的一种意想不到的、多模式且直接的参与。本文旨在讨论，HELLS是如何通过不同且特定情境下的机制，调控一组功能相关基因的表达，从而促进转录的可塑性与表型适应性，最终维护基因组的组织与稳定性。

参与DNA methylation

参与DNA damage repair

作为transcriptional sentinel

转录、DNA 复制和修复期间，染色质结构被连续修饰，从而暴露特定基因区域，并使 DNA 互作酶进入 DNA。依赖于 ATP 的染色质重构复合体会利用 ATP 水解的能量来重新定位、组装、迁移和重组核小体，从而改变染色质结构。这些复合体存在一个保守的 SNF2 样催化 ATP 酶亚基，该亚基属于以下四个家族中的一个：SWI/SNF、CHD/Mi-2、ISWI/SNF2L 和 INO80。依赖于 ATP 的染色质重构物在发育、癌症和干细胞生物学中发挥关键作用。

哺乳动物转换/蔗糖不发酵 (SWI/SNF) 家族也称 BAF 复合体（Brg/Brm 相关因子），被认为能改变核小体定位和结构，从而调控基因表达。SWI/SNF 复合体的 ATP 酶亚基是 BRM 或 BRG1；这些分子还包含结合乙酰化赖氨酸残基的溴结构域。BAF 复合体存在于各种细胞特异性、最近确定的、疾病特异性的异源构型中，每种构型共含有 12-14 个亚基，但始终包括核心亚基 BRM、或 BRG1、BAF170、BAF155 和 BAF47（也称 hSNF5）。这些构型会在细胞命运决定期间发生变化，例子包括胚胎干细胞中的 esBAF、神经元祖细胞中的 npBAF，以及分裂期后神经元中的 nBAF，它们每个均含特定亚基构型。这些编码 BAF 复合体组分的基因在超过 20% 的人癌细胞中会发生突变，并且已成为集中抗癌努力工作的中心。

染色质域解旋酶 DNA 结合 (CHD) ATP 酶家族有一个标签染色质域，它会结合甲基化赖氨酸残基。这个家族的 ATP 酶亚基包括 CHD1-9。但因其在核小体重构和脱乙酰酶 (NuRD) 复合体中发挥作用，对 CHD3 和 4 的特征鉴定最为广泛。较大的多亚基 NuRD 复合体含有 HDAC1 和 2 种蛋白，结合具有组蛋白脱乙酰酶活性的 ATP 依赖性染色质重构，从而在胚胎发育和癌症期间调节转录激活和抑制。

模拟转换 (ISWI) 家族可调控核小体滑动和间隙。ISWI 复合体中的催化 ATP 酶是 SNF2L 或 SNF2H，可将 1-3 个辅亚基组装成为 7 独特的复合体。该家族的创始成员核小体重构因子 (NuRF) 含有 SNF2L，并且是发育期间基因激活所必需的。

人 INO80 家族中的 ATP 酶包括 INO80、Tip60 和 SRCAP，它们可组装成为较大的多亚基复合体，以将变异的组蛋白交换成为染色质结构。人 INO80 会驱逐核小体来辅助修复双链断裂，从而让修复因子进入 DNA。

###### 基因家族

HELLS属于SNF2家族

Human HELLS – also known as lymphoid specific helicase (Lsh), SMARCA6, or PASG

###### Structure of HELLS

- two helicase ATPase domains (解旋酶 ATP 酶活性结构域)

- Nucleosome positioning during transcription is dynamically regulated by ATP dependent chromatin remodeling enzymes. These enzymes can evict histone octamers, exchange histones, and manipulate nucleosome structure through sliding and distortion

- an autoinhibitory domain that restricts its intrinsic nucleosome remodeling activity in vitro

###### Function of HELLS

- primarily expressed in proliferating lymphoid tissues and stem cells
- HELLS mutations contribute to the rare immunodeficiency–centromeric instability–facial anomalies (ICF) syndrome, characterized by immunodeficiency, developmental defects, and mental retardation
- reshapes chromatin, influencing the binding of RNA polymerase (RNAP) and specificTFs, fine-tuning the expression of cell-identity associated transcriptional programs
- Catalyzing the incorporation of specific histone variants (**macroH2A1** and **macroH2A2** histones) into single nucleosomes. MacroH2A incorporation is usually linked to transcriptional repression, and HELLS utilizes this mechanism primarily in repetitive sequences and distal and proximal developmental enhancers where it exerts its silencing effects
- Slide nucleosomes

- In embryonic stem cells, HELLS-dependent sliding affects CpG sites exposed to DNA methyltransferase activity, contributing to the formation of pericentromeric heterochromatin foci
- HELLS can slide nucleosomes in only a single direction and in the presence of the cell division cycle associated 7 (CDCA7) protein, which is necessary for the full functionality of HELLS

- specific remodeling mechanisms
- **promote transcription**

- enhances promoter accessibility by creating nucleosome-deprived regions (NDRs). These NDRs serve as binding platforms for RNA polymerase and transcription factors, thereby guaranteeing transcriptional initiation

- HELLS interactions with other remodeling complexes, nucleosomes, and other transcriptional regulators are ***cell-type specific***. These findings support the hypothesis that remodeling functions of HELLS and, consequently, its ability to ***repress*** or **promote** transcription may be ***context-dependent***
- **HELLS and transcriptional priming**

- **Tens of thousands of regulatory elements** undergo a dynamic shift between active and inactive states during development and differentiation, driving a concerted change in chromatin structure
- HELLS pervasively occupies the mammalian genome and directly influences the accessibility of enhancers and promoters, contributing to the overall distribution of nuoleosomes and the stability of chromatin states
- During embryonic development, the regulation of **enhancer–promoter communication** is crucial for lineage commitment. This interplay serves to orchestrate RNAP recruitment, thereby priming transcription and ultimately contributing to the activation of specific genes.
- TFs play a crucial role in this communication, not only by **recognizing specific DNA sequences** and **influencing local chromatin accessibility**, but also by **recruiting chromatin remodelers** that shape the three dimensional topological organization of the genome.
- **During the early stages of embryogenesis**, HELLS limits the accessibility of distal and proximal developmental enhancers and reduces the engagement of **lineage-specific TFs** such as GATA binding protein 3 (**GATA3**), myogenic differentiation 1 (**MYOD**), SRY-box transcription factor 6 (**SOX6**) and achaete–scute family basic helix–loop–helix (**BHLH**) transcription factor 1 (**ASCL1**)
- **During development**, HELLS shuts down the expression of pluripotency genes such as a subset of homeobox (**Hox**) and POU class 5 homeobox 1 (**Oct4**). In these contexts, HELLS alters the chromatin landscape in part by catalyzing the incorporation of **macroH2A1** and **macroH2A2** histones. (A图) This creates an inaccessible chromatin landscape that acts as a highly energetic barrier to RNAP passage. It is plausible that HELLS'ability to cooperate with DNA methyltransferases contributes to the faster propagation of these repressed chromatin states.
- Nevertheless, HELLS has been shown to cooperate directly with different **transcription factors** to modulate specific gene expression programs. This relationship is frequently restrained in cancer, where the shifts in chromatin organization drive tumorigenesis leading to a globally dysregulated state. A growing number of studies have revealed that HELLS is abnormally expressed in human cancers. Also in these settings, HELLS has been largely associated with active transcriptional elements such as enhancers and promoters, which fuel the increased overall transcription needed for tumor cell proliferation. **A recent study revealed that HELLS modifies chromatin accessibility by creating NDRs at immune-related promoters in T cell lymphoma cells**. While the exact mechanism remains elusive, this process appears to facilitate RNAP recruitment and TF binding, ultimately leading to enhanced transcriptional activity. The promoters of immune-related genes are associated with enriched levels of **H3K4me3**. This mark is normally found around the transcriptional starting site of actively transcribed genes, further indicating that changes in the entire chromatin structure are necessary for their precise gene expression. Notably, this set of genes, like those of cell identity during the differentiation, can be activated and transcribed within minutes after stimulation. Recruitment of RNAP at the target promoter is a crucial step for these genes. A delay in this step has catastrophic consequences for the cell, with a delay in primary response and the execution of transcriptional programs.

- **HELLS and TFs: a complex dance in gene regulation**

- HELLS can act as a potent transcriptional co-activator, physically interacting with TFs to enhance their recruitment and DNA-binding affinity at target gene promoters. This function as a co-activator has been exemplified, for the first time, by the interaction with E2F transcription factor 3 (E2F3). This occurs through the E2F3 coiled-coil domain and the interaction is stabilized by the E2F3-marked box. **HELLS–E2F3 interaction aids the induction of E2F-target genes and cell-cycle re-entry, establishing a proliferative circuit.** This network is also restrained in tumors with sustained cell proliferation and tumor aggressiveness. Von Eyss et al. showed that 74% of all HELLS-bound promoters display an E2F-like motif and that a massive surge of E2F3A at E2F promoters cannot compensate for the loss of HELLS in the target gene and S-phase induction (B图). Although the direct association with RNAP occupancy has not been investigated, most HELLS-bound promoters overlap with the active marker of transcription **H3K4me3**, further indicating the creation of a permissive environment for RNAP recruitment.
- Recent findings demonstrated that HELLS’ repertoire extends beyond E2Fs. HELLS also promotes YY1 transcription factor (**YY1**) transcriptional activity by facilitating its recruitment to target genes. This interaction is essential for ensuring the aberrant expression of cytoskeleton-associated genes and plays a role in tumor aggressiveness. The loss of HELLS leads to YY1 displacement from DNA in lymphoma cells, indicating a precise hierarchy that selectively drives gene programs. Collectively, HELLS gains access to lineage-specific factors to their respective binding sites, ensuring the execution of precise transcriptional programs. The interplay between HELLS and TFs offers potential therapeutic targets for cancer and other diseases. Targeting HELLS interactions with transcriptional factors could disrupt selective transcriptional networks and halt disease progression.

- **HELLS and R-loops: a dynamic duo in the regulation of RNAP elongation**

- Transcription is a primary source of genome instability. The unwinding of DNA by RNAP during elongation generates torsional stress and is a major source of DNA supercoiling throughout the genome. Stable RNA–DNA hybrids formed between the nascent RNA and the DNA upstream of the RNAP, known as R-loops, can hinder both the elongation and the stability of the chromatin template.
- When massive transcription is required, such as in sustaining the proliferation of cancer cells, the elongating RNAP alone is not able to transcribe through the gene body due to the structural impediments imposed by the R-loops. Thus, RNAP passage is likely to require assistance in moving through nucleosomes without unscheduled obstacles. A recent study has demonstrated that HELLS co-localizes with R-loops, and its dysregulation results in the accumulation of R-loops nearby or at the same sites where RNAP stalls. This phenomenon also induces the accumulation of damaging events on the same genomic sites affected by R-loop persistence, leading to genomic instability in lymphoma. HELLS creates a permissive chromatin landscape in which the RNAP can successfully elongate, increasing the transcript level. This specific regulation occurs in selected target genes central to cancer cell structure maintenance, such as Rho-GTPase and cytoskeleton organization. Due to their structural nature, these genes are required to be transcribed at high levels and in a continuum manner to guarantee cellular support. The molecular mechanisms underlying HELLS involvement in resolving R-loops are likely to be multitiered and remain to be elucidated. Based on its pleiotropic activities, HELLS may help resolve R-loops through different mechanisms. HELLS may remodel nucleosome positioning in R-loop-flanking regions, thus making chromatin accessible to RNA-helicase DExD-box helicase 21 (DDX21) and the facilitates chromatin transcription (FACT) complex, which generally resolves R loops in those regions (C图).
- Alternatively, based on ATP-binding domain sequence homology with its ortholog in plant decrease in DNA methylation 1 (DDM1), HELLS could clear cotranscriptional R-loops directly. Given the importance of HELLS in development and tumorigenesis, establishing the exact principles of HELLS-mediated resolution of R loops is important for understanding the mechanisms of cancer propensity and identifying new therapy targets.



###### Questions about HELLS

- The first includes understanding its recruitment to target genes. As a chromatin remodeler, HELLS lacks DNA sequence specificity. Presumably, beyond CDCA7, other pioneering TFs act as interpreters, providing the specificity of HELLS in establishing cell identity and responding to environmental cues. 
- Second, what is the precise mechanism through which HELLS makes chromatin accessible to RNAP and TFs? HELLS could exert this function by the eviction or sliding of nucleosomes favoring the binding of locus-specific TFs priming the transcription.
- By virtue of its central and multifunctional functions in tumors, there is substantial interest in identifying compounds capable of inhibiting HELLS activity. Such pharmacological inhibitors hold promise not only as monotherapy but also in synergistic combination with conventional and targeted therapies. HELLS downregulation could potentially circumvent resistance to DNA damaging agents by hindering repair mechanisms and disrupting critical gene expression networks



<img src="https://mushan-guan.github.io/img1.jpg" style="zoom:33%;" >



<img src="https://mushan-guan.github.io/img2.png" style="zoom:70%;" >

Figure 1. Transcriptional mechanisms regulated by helicase lymphoid specific (HELLS). HELLS regulates transcription through different modalities and in a context-dependent manner. During the establishment of cell identity and cell fate, HELLS directly influences the accessibility of chromatin by depositing the histone variant MacroH2A through its ATP-binding domain. The ability of HELLS to cooperate with DNA methyltransferases (DNMTs) may facilitate the rapid propagation of repressed chromatin states. This mechanism leads to the silencing of developmental enhancers and the control of enhancer–promoter communication (A). During early cellular transformation and subsequent tumor progression, HELLS drives aberrant and excessive transcription by altering chromatin accessibility in an ATP-dependent manner. HELLS induces the formation of nucleosome-depleted regions (NDRs) at promoters of tumor cells, facilitating the recruitment of RNA polymerase (RNAP) and transcription factors (TFs) to target genes. HELLS employs this mechanism in E2F transcription factor 3 (E2F3)-dependent G1/S cell cycle genes and in immune related genes that require rapid transcriptional activation upon stimulation (B). In genes essential for maintaining cancer cell structure, characterized by high transcriptional activity, HELLS restricts the formation of co-transcriptional R-loops. This may be achieved through nucleosome remodeling in the vicinity of R-loops, thereby facilitating access to the RNA helicase DDX21 and the facilitates chromatin transcription (FACT) complex. Consequently, HELLS promotes efficient RNAP elongation, contributing to tumor aggressiveness (C).

图1. 由淋巴特异性解旋酶（HELLS）调控的转录机制。

HELLS 通过不同的方式并以情境依赖的方式调控转录。

在细胞身份与命运建立的过程中，HELLS 通过其 ATP结合结构域 介导 组蛋白变体 MacroH2A 的沉积，从而直接影响染色质的可及性。HELLS 与 DNA甲基转移酶（DNMTs） 的协同作用，可能有助于 抑制性染色质状态的快速传播。该机制可导致 发育增强子沉默 以及对 增强子与启动子之间通讯的调控（图A）。

在早期细胞转化及后续肿瘤进展过程中，HELLS 通过 ATP依赖性方式改变染色质可及性，推动 异常且过度的转录。HELLS 在肿瘤细胞启动子区域诱导 核小体耗竭区（NDRs） 的形成，从而促进 RNA聚合酶（RNAP） 和 转录因子（TFs） 向靶基因的募集。HELLS 利用此机制，调控 依赖E2F转录因子3（E2F3）的G1/S细胞周期基因，以及那些在刺激下需要快速激活的 免疫相关基因（图B）。

在那些对维持癌细胞结构至关重要、具有高转录活性的基因中，HELLS 抑制 共转录R-环结构（R-loops） 的形成。这可能通过对 R-环邻近区域的核小体重塑 实现，从而促进 RNA解旋酶DDX21 以及 染色质转录促进因子复合物（FACT） 的可及性。因此，HELLS 有助于 RNA聚合酶的有效延伸转录，从而促进肿瘤的侵袭性（图C）。





<br>

2025 Genome Biol. Alexander Meissner. HELLS is required for maintaining proper DNA modification at human satellite repeats



<br>

2025 Cell Death Dis. Jueng Soo You. HELLS controls mitochondrial dynamics and genome stability in liver cancer by collusion with MIEF1

![img](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41419-025-07589-x/MediaObjects/41419_2025_7589_Figa_HTML.png)

本研究探究了HELLS的致癌机制。通过基因敲除与过表达，发现线粒体延伸因子1（MIEF1） 是HELLS分子网络在肝癌中的关键靶点。在预后不良的肝癌患者中，MIEF1表达水平显著升高，而抑制MIEF1表达则会削弱肿瘤能力，表明MIEF1是肝癌中的一个致癌基因。抑制HELLS-MIEF1轴会引起线粒体过度融合、能量耗竭，并进一步诱导细胞衰老。HELLS的敲低会全局性地增强组蛋白H3第9位赖氨酸三甲基化（H3K9me3），特别是在染色质热点区域，与 SUV39H1的上调及进一步的 DNA甲基化增加相关。这一过程稳定了基因组，并形成了过度融合的线粒体，从而减少了ROS和DNA损伤的水平。最终，肿瘤细胞进入饥饿和平静的状态。我们还通过MIEF1过表达和线粒体融合药物，进一步验证了 HELLS-MIEF1 轴的功能。



<br>

## GPNMB | PLD1

<br>

2025 ***Brain Res***. *Xiaobo Li*. GPNMB attenuates neuroinflammation and improves ischemic stroke via modulation of PI3K/Akt and p38 MAPK signaling pathways

在缺血性脑组织中，**GPNMB**表达显著上调，其表达在MCAO后的第3-7天达到峰值。在缺血性脑卒中患者中，血清 GPNMB 水平升高，并与卒中严重程度呈正相关。敲低GPNMB会加重脑卒中的不良结局，增强神经炎症，并导致更严重的神经元损伤。从机制上看，GPNMB 正调控PI3K/Akt/GSK3β 信号通路，同时负调控p38 MAPK、JNK和ERK通路。此外，GPNMB 的敲低会增强NF-κB的表达，后者是炎症反应的核心转录调控因子。



<br>

## Stroke

<br>

transient middle cerebral artery occlusion (tMCAO)

OGD model

transient focal cerebral ischemia (tFCI)

brain water content

laser Doppler and laser speckle to monitor  regional cerebral blood flow (rCBF) of the parietal cortex in mice

infarct volume

T2 weightedmagneticresonanceimaging(MRI)

National Institutes of Health Stroke Scale (NIHSS)

modified Rankin Scale (mRS)

modified neurological severity score (mNSS)

Longa score

sensorimotor functions: Garcia score test, rotarod test, adhesive removal test

cognitive: Morris water maze

foot fault test

grip strength

细胞周期检查: DyeCycle staining

electrophysiology was then used to ex amine the long- term functional integrity of white matter manifested as the nerve conduction by evoking and recording the compound action  potentials (CAPs) in the corpus callosum. The results showed that  tFCI decreased the amplitudes of the N1 and N2 segments, represent ing the fast conduction of myelinated axons and the slow conduction  of unmyelinated axons, respectively.



<br>

## Immune

<br>

damage-associated molecular patterns (DAMPs)

pro-inflammatory factors: IL-1β, IL-6, IL-17, IL-21, TNFα, interferon-γ, Tnf, Il1b, Cxcl10, Il1a, Nfkbib

anti-inflammatory genes: Ccl22, Arg1, Ccl7, Itgax, Mmp12

neurotrophic factors

synaptic reg ulatory molecules

microglial activation: Iba-1

M1型小胶质细胞具有强大的吞噬作用，主要分泌促炎因子，发挥促炎功能，引起细胞凋亡及继发损伤，过度活化的M1型小胶质细胞具有明显的神经毒性作用。

M1巨噬细胞/小胶质细胞: CD86, CD16, CD32, MHC-Ⅱ, iNOS, IL-1β, IL-6, TNF-α, CCL-3, CCL-5

M2型小胶质细胞又分为M2a、M2b、M2c 3种亚型，可分泌抗炎细胞因子，在血管生成、促进炎症修复方面起重要作用。

M2巨噬细胞/小胶质细胞: CD206, CD163, Msr1, Arg-1, Fizz-1, IL-10, YM1/2, TREM2, TGF-β, CCL22

p65: the main subunit of nuclear factor-κB (NF-κB)

glycogen synthase kinase 3β (GSK3β)

p38 mitogen-activated protein kinase (MAPK)

c-Jun N-terminal kinase (JNK)

extracellular signal-regulated kinase (ERK)

phosphoinositide 3-ki nase (PI3K)/Akt



<br>

## Drug | Stain

<br>

CSF1R抑制剂类小胶质细胞清除剂: PLX5622, PLX3397

小胶质细胞清除: CXCR1creER:iDTR transgenic mice and diphtheria toxin

巨噬细胞清除剂: clodronate liposomes

Aβ的荧光染料: Methoxy-X04、thioflavine-S、Thiazine Red

days post-injury (dpi)

cell survival: Annexin V/PI

cell viability: MTT assay

白质染色: SMI32 (a neurofilament marker) and MBP (a key myelin protein)

SMI32/MBP ratio越低代表越好

新生少突胶质细胞染色: APC+ BrdU+ 

新生少突胶质细胞前体染色: PDGFRα+ BrdU+

新生血管染色: CD31+ BrdU+ ZO-1+

pH3: a mitotic chromosome condensation marker labeling anaphase and telophase



<br>

## Geneset

<br>

myelination相关基因: Ndrg1, Degs1, Mag, Mog, Plp1, Cnp, Igf1, Gjc2, Afdn, Trf

angiogenesis相关基因: Pkm, S100a1, Pamp2, Itgb1, Grn, Lgals3

pro angiogenic phenotype: Igf1, Grn, Lgals3, Ang, Ccl2, Pdgfra, Vegfb, Pf4, Anpep, Flt1, Hgf

immediate early genes: Egr1, Jund, Klf2

G1-S phase: Pcna, Cdk2, and Ccne1

G2- M phase: Cdk1, Ccnb1, and Birc5

M phase: Kntc1, Cdca8, and Sgo1



<br>

## Lipid

<br>

myelin debris phagocytosis: Trem2

lipid storage in lipid droplets: Plin2, Plin3, Soat1

lipid storage: BODIPY

lipid hydrolysis: Nceh1, Lpl, Pla2g7

lipid metabolism regulation: Nr1h3

lipid efflux: Abca1

lipid transport: Apoe, Apoc1, Apoc2, Npc1

phosphatidylcholine (PC)

fatty acid (FA)

phosphatidylethanolamine (PE)

lysophosphatidylcholine (LPE)

cholesterolester (ChE)

triglyceride (TG)



<br>

## Flow Cytometry

<br>

microglia: CD45intCD11b+Ly6G−CD11C−

macrophages: CD45+CD11b+F4/80+Ly6G−CD11C−

neutrophils: CD45+CD11b+F4/80− 

oligodendrocytes: CD45+CD11b−O4+

